Dr. Sadelain is the incumbent of the Stephen and Barbara Friedman chair and the founding director of the Center for Cell Engineering at MSKCC. He previously served on the board of directors of the American Society of Gene Therapy (2004-2007) and continues to serve on the editorial boards of Molecular Therapy, Human Gene Therapy and Gene Therapy.
T cell engineering is a promising approach to establish potent and durable immunity against cancer. The genetic modification of T lymphocytes is emerging as a powerful approach to investigate T cell function in vivo and, potentially, to bolster cancer immunotherapy. Dr. Sadelain’s research focuses on novel approaches to enhance T cell costimulation and function. His clinical program focuses on B cell malignancies, including on-going studies with CD19-targeted T cells in chronic lymphocytic leukemia and upcoming studies in acute leukemia and lymphoma, as well as solid tumors, including upcoming studies in metastatic prostate cancer.